|Bid||85.00 x 200|
|Ask||199.00 x 1500|
|Day's Range||125.91 - 127.38|
|52 Week Range||87.49 - 130.29|
|PE Ratio (TTM)||95.26|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.
Here we take a peek at Varian Medical's (VAR) performance to analyze why investors should hold on to this stock despite adversities.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Over the last one-month, outflows of investor capital in ETFs holding VAR totaled $16.57 billion.
Should Investors Be Interested in Varian Medical Systems? Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution. Since the launch of this radiotherapy solution in 4Q16, the company has secured 57 orders, of which 19 were placed in 1Q18.
Should Investors Be Interested in Varian Medical Systems? In 1Q18, Varian Medical Systems (VAR) reported revenues of $356.7 million from the Americas region, which was a YoY (year-over-year) growth of 20% on a reported as well as constant currency basis. The company reported revenue of $193 million from EMEA (Europe, the Middle East, and Africa) sales in 1Q18, which is a YoY rise of 5% on a reported basis but a decline of 2% on a constant currency basis.
Should Investors Be Interested in Varian Medical Systems? In 1Q18, Varian Medical Systems (VAR) reported new orders worth $620 million for its oncology systems business. It had a total order backlog worth $2.7 billion at the end of 1Q18, which is a YoY rise of 7%.
Should Investors Be Interested in Varian Medical Systems? In 1Q18, Varian Medical Systems (VAR) reported revenues of $679 million, which is a YoY (year-over-year) rise of 13% on a reported basis and an 11% rise on a constant currency basis. It was mainly driven by increased sales of its linac (linear accelerator) systems in the oncology operating segment.
On March 14, 2018, Varian Medical Systems (VAR) announced that its acquisition of Sirtex Medical (SXMDF) has received regulatory clearances from the US antitrust authorities as well as the FCO (German Federal Cartel Office). The acquisition was announced on January 29, 2018, and entails the acquisition of all outstanding shares of Sirtex Medical by Varian Medical Systems for $1.3 billion.
The cancer diagnosis and therapy company acknowledged that 2017 had been a "challenging year", with project delays and tougher competition in the proton therapy market, part of the reason it forecast an operating loss in a warning in January. The company makes machines that deliver cancer-fighting proton beams, a super precise form of radiation, but it has been beset by delays in the construction of buildings to house its proton therapy systems by third party contractors. IBA was focusing on strict cost management and hiring expenses, but still cautious about orders being finalised, Chief Executive Olivier Legrain told Reuters.
Wright Medical (WMGI) is focusing on product innovation through research and development. Also, the company is focusing on strategic acquisition and divestitures.